April 15th 2025
One expert's take on reshoring pharma manufacturing services in the US amid likely tariffs to drugs looming.
A panel discussion uncovers ways to deliver personalized therapy ops in a timely fashion.
April 8th 2025
How data-driven insights can help pharma companies balance their revenue management and innovation strategies—including resource allocation, pricing, and market access.
April 4th 2025
The parties aim to create an end-to-end digital thread that links research data all the way through to life sciences manufacturing.
April 3rd 2025
In a move meant to encourage domestic production, the president’s executive order features a 10% baseline tax, expected to take effect April 9.
New life sciences capital-construction projects totaled $15 billion in 2015
Construction index shows a steady level of North American activity
New year, new names for BIO and Canada's pharma trade association, and more
'Innovation' is the recurring theme
Full-line distributor sales reached $350 billion in 2013, representing 91% of pharma sales
HDMA's 2015-16 Factbook updates member financial, operational performance
Biosimilars: why deep discounts may become the dominant paradigm
European experience to date indicates a changing perspective on biosimilar pricing
A Conversation with George Barrett, Cardinal Health
Resources for managing global drug pricing decisions are limited, says survey
Model N/Highpoint survey points to better integration of pricing and contract data
Daiichi Sankyo US shifts to specialty-pharma focus; cuts US staff by nearly 50%
Company has 18 products in its US pipeline
A Conversation with Steve Collis, AmerisourceBergen
A Conversation with Gary McWalters, TGaS Advisors
Biotech had a 'colossal' year in 2014 for revenue and capital formation, says EY
Annual Beyond Borders report charts a boom that is continuing into 2015
CVS Health takes over Target's in-store pharmacies and clinics in a $1.9-billion deal
Rebranding will affect 1,660 pharmacies and 80 clinics
McKesson's Paul Julian is HDMA's 2015 Nexus winner
Diana awards for Apotex, Eisai, Depomet and Bayer Healthcare in manufacturing
AmerisourceBergen will build three new DCs; Cardinal tucks in Harvard Drug Corp.
Olive Branch, MS; Shakopee, MN; and Newburgh, NY are the designated ABC sites
A Conversation with Shabbir Dahod, TraceLink
Accenture finds an industry turnaround in 'future value'
Novo Nordisk is tagged as the only 'high performer'
US spending on drugs hit $373.9 billion in 2014, up 13.1%
Effect of the first full year of Obamacare was muted, although a record number of prescriptions were written
H. D. Smith reorganizes, expands upper management
Creation of a holding company streamlines future acquisitions; focus is on specialty drug services
A conversation with W. Scott Evangelista, Quintiles
Campbell Alliance updates, expands its commercial launch consulting services
More executional capabilities derive from affiliation with parent, inVentiv Health
Rite Aid to buy EnvisionRx, continuing a reshaping of US drug distribution
$2-billion acquisition brings a $5-billion/yr PBM to Rite Aid's 4,600 retail stores
Independent physicians and their clinics remain a dominant channel for specialty distribution, says HDMA
Association's annual specialty-distribution study focuses trend in oncology, chronic diseases
Next agg-spend deadline looms with little buzz from industry
Reporting by pharma companies on spending on physicians is becoming a non-event
The biosimilars payoff in the US might be small and fleeting
Analysis from Prime Therapeutics points to severe cost hurdles for biosimilars developed and marketed in the US
ACOs raise the stakes for evidence-based medicine
Manufacturers will need to refine their interactions with healthcare providers and produce better outcomes research and adherence programs to compete
With acquisition of OptumHealth assets, Mapi Group bids to capture health economics consulting work globally
Mapi Group casts itself as a leading 'health research and commercialization' player
Walgreens-Alliance Boots tie-up is formally approved
So long WAG, hello to WBA as pharma manufacturers look at a consolidating buyer landscape
Hepatitis C therapies multiply and price concessions appear behind the scenes
Express Scripts touts a 'fundamental change' in drug pricing; others would call it negotiating a discount
Managing government pricing programs
When state and federal governments are involved, prices and reimbursements have both regulatory and financial consequences
A conversation with Phil Hagerman, Diplomat Pharmacy
BioNJ industry survey sees biotech establishment growth but employment decline
A big jump in 2012-2013 venture funding will fuel growth; BMS' new facility